NCT06671392

A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension

A Multi-center, Randomized, Double-blind, Parallel Design, Phase III Study to Evaluate and Compare the Efficacy and Safety of DWC202405/DWC202313 and DWC202314 Combination Therapy to DWC202405/DWC202313 in Patients With Essential Hypertension Inadequately Controlled With DWC202405

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 198 (actual)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A Multi-center, Randomized, Double-blind, Parallel design, Phase III study to Evaluate and Compare the Efficacy and Safety of DWC202405/DWC202313 and DWC202314 Combination Therapy to DWC202405/DWC202313 in Patients with Essential Hypertension Inadequately Controlled with DWC202405

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	DWC202405	5/20mg, 1 tablet, Oral, Once a day
DRUG	DWC202405, DWC202314	5/20mg + 1.5mg, 1 tablet, Oral, Once a day
DRUG	DWC202405, DWC202314P	5/20mg + 1.5mg, 1 tablet, Oral, Once a day
DRUG	DWC202313, DWC202314	10/40mg + 1.5mg, 1 tablet, Oral, Once a day
DRUG	DWC202313, DWC202314P	10/40mg + 1.5mg, 1 tablet, Oral, Once a day

Timeline

• Start date: 2025-02-24
• Primary completion: 2026-02-05
• Completion: 2026-02-05
• First posted: 2024-11-04
• Last updated: 2026-03-19

Locations

1 site across 1 country: South Korea